Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates

Infection and Immunity

Volumn 76, Issue 6, 2008, Pages 2333-2340

  Via, Laura E ^a   Lin, P Ling ^b,c   Ray, Sonja M ^a   Carrillo, Jose ^a   Allen, Shannon Sedberry ^d   Seok, Yong Eum ^e   Taylor, Kimberly ^a   Klein, Edwin ^c   Manjunatha, Ujjini ^a   Gonzales, Jacqueline ^a   Eun, Gae Lee ^a   Seung, Kyu Park ^e,f   Raleigh, James A ^h   Sang, Nae Cho ^g   McMurray, David N ^d   Flynn, JoAnne L ^c   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d TEXAS A M COLLEGE OF MEDICINE   (United States)

^e International Tuberculosis Research Center   (South Korea)

^f Ministry of Health and Welfare   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; PIMONIDAZOLE; RIFAMPICIN; DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXYGEN; RADIOSENSITIZING AGENT; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATMOSPHERE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; FIBER OPTICS; GUINEA PIG; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFECTION; LUNG GRANULOMA; LUNG PARENCHYMA; MOUSE; NECROSIS; NONHUMAN; OXYGEN TENSION; PRIMATE; PRIORITY JOURNAL; RABBIT; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GRANULOMA; HUMAN; LUNG; LUNG TUBERCULOSIS; MACACA; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY;

ANIMALS; ANOXIA; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; GRANULOMA; GUINEA PIGS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; MACACA FASCICULARIS; METRONIDAZOLE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXYGEN; RABBITS; RADIATION-SENSITIZING AGENTS; TUBERCULOSIS, PULMONARY;

EID: 46249108568     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01515-07     Document Type: Article

References (47)

1. Allen, J. G., S. Dische, I. Lenox-Smith, S. L. Malcolm, and M. I. Saunders. 1984. The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans. Eur. J. Clin. Pharmacol. 27:483-489.
2. Aly, S., T. Laskay, J. Mages, A. Malzan, R. Lang, and S. Ehlers. 2007. Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis. J. Pathol. 212:295-305.
3. Aly, S., K. Wagner, C. Keller, S. Malm, A. Malzan, S. Brandau, F. C. Bange, and S. Ehlers. 2006. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210:298-305.
4. Arteel, G. E., R. G. Thurman, and J. A. Raleigh. 1998. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur. J. Biochem. 253:743-750.
5. Arteel, G. E., R. G. Thurman, J. M. Yates, and J. A. Raleigh. 1995. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72:889-895.
6. Brooks, J. V., S. K. Furney, and I. M. Orme. 1999. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43:1285-1288.
7. Capuano, S. V., III, D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin, S. Bissel, C. Fuhrman, E. Klein, and J. L. Flynn. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:5831-5844.
8. Dahl, J. L., C. N. Kraus, H. I. Boshoff, B. Doan, K. Foley, D. Avarbock, G. Kaplan, V. Mizrahi, H. Rubin, and C. E. Barry III. 2003. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl. Acad. Sci. USA 100:10026-10031.
9. Dannenberg, A. M. 2006. Pathogenesis of human pulmonary tuberculosis: insights from the rabbit model. ASM Press, Washington, DC.
10. Desai, C. R., S. Heera, A. Patel, A. B. Babrekar, A. A. Mahashur, and S. R. Kamat. 1989. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J. Assoc. Physicians India 37:694-697.
11. Dhillon, J., B. W. Allen, Y. M. Hu, A. R. Coates, and D. A. Mitchison. 1998. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2:736-742.
12. Durand, R. E., and J. A. Raleigh. 1998. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58:3547-3550.
13. Gomez, J. E., and J. D. McKinney. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinburgh) 84:29-44.
14. Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 157:1436-1440.
15. Haapanen, J. H., I. Kass, G. Gensini, and G. Middlebrook. 1959. Studies on the gaseous content of tuberculous cavities. Am. Rev. Respir. Dis. 80:1-5.
16. Idkaidek, N. M., and N. M. Najib. 2000. Enhancement of oral absorption of metronidazole suspension in humans. Eur. J. Pharm. Biopharm. 50:213-216.
17. Im, J. G., H. Itoh, Y. S. Shim, J. H. Lee, J. Ahn, M. C. Han, and S. Noma. 1993. Pulmonary tuberculosis: CT findings - early active disease and sequential change with antituberculous therapy. Radiology 186:653-660.
18. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
19. Kaplan, G., F. A. Post, A. L. Moreira, H. Wainwright, B. N. Kreiswirth, M. Tanverdi, B. Mathema, S. V. Ramaswamy, G. Walther, L. M. Steyn, C. E. Barry III, and L. G. Bekker. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71:7099-7108.
20. Kaplan, G., W. C. Van Voorhis, E. N. Sarno, N. Nogueira, and Z. A. Cohn. 1983. The cutaneous infiltrates of leprosy. A transmission electron microscopy study. J. Exp. Med. 158:1145-1159.
21. Kennedy, H. E., H. M. Vandiviere, I. G. Melvin, and H. S. Willis. 1957. The treated pulmonary lesion and its tubercle bacillus. III. Drug susceptibility studies. Am. J. Med. Sci. 233:676-684.
22. Lasco, T. M., O. C. Turner, L. Cassone, I. Sugawara, H. Yamada, D. N. McMurray, and I. M. Orme. 2004. Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun. 72:1147-1149.
23. Lenaerts, A. J., D. Hoff, S. Aly, S. Ehlers, K. Andries, L. Cantarero, I. M. Orme, and R. J. Basaraba. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51:3338-3345.
24. Long, R., B. Maycher, A. Dhar, J. Manfreda, E. Hershfield, and N. Anthonisen. 1998. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 113:933-943.
25. Loring, W. E., and H. M. Vandiviere. 1956. The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis. Am. J. Med. Sci. 232:20-29.
26. McKinney, J. D., and J. E. Gomez. 2003. Life on the inside for Mycobacterium tuberculosis. Nat. Med. 9:1356-1357.
27. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134.
28. Paramasivan, C. N., G. Kubendiran, and D. Herbert. 1998. Action of metronidazole in combination with isoniazid and rifampicin on persisting organisms in experimental murine tuberculosis. Indian J. Med. Res. 108:115-119.
29. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
30. Poey, C., F. Verhaegen, J. Giron, J. Lavayssiere, P. Fajadet, and B. Duparc. 1997. High resolution chest CT in tuberculosis: evolutive patterns and signs of activity. J. Comput. Assist. Tomogr. 21:601-607.
31. Raleigh, J. A., D. P. Calkins-Adams, L. H. Rinker, C. A. Ballenger, M. C. Weissler, W. C. Fowler, Jr., D. B. Novotny, and M. A. Varia. 1998. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:3765-3768.
32. Raleigh, J. A., S. C. Chou, E. L. Bono, D. E. Thrall, and M. A. Varia. 2001. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int. J. Radiat. Oncol. Biol. Phys. 49:569-574.
33. Raleigh, J. A., S. C. Chou, D. P. Calkins-Adams, C. A. Ballenger, D. B. Novotny, and M. A. Varia. 2000. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin. Cancer Res. 6:855-862.
34. Reed, M. B., P. Domenech, C. Manca, H. Su, A. K. Barczak, B. N. Kreiswirth, G. Kaplan, and C. E. Barry III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87.
35. Sever, J. L., and G. P. Youmans. 1957. The enumeration of nonpathogenic viable tubercle bacilli from the organs of mice. Am. Rev. Tuberc. 75:280-294.
36. Sever, J. L., and G. P. Youmans. 1957. Enumeration of viable tubercle bacilli from the organs of nonimmunized and immunized mice. Am. Rev. Tuberc. 76:616-635.
37. Sever, J. L., and G. P. Youmans. 1957. The relation of oxygen tension to virulence of tubercle bacilli and to acquired resistance in tuberculosis. J. Infect. Dis. 101:193-202.
38. Shim, H. J., Y. C. Kim, J. H. Lee, J. W. Kwon, W. B. Kim, Y. G. Kim, S. H. Kim, and M. G. Lee. 2005. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos. 26:269-277.
39. Tsai, M. C., S. Chakravarty, G. Zhu, J. Xu, K. Tanaka, C. Koch, J. Tufariello, J. Flynn, and J. Chan. 2006. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 8:218-232.
40. Ulrichs, T., G. A. Kosmiadi, S. Jorg, L. Pradl, M. Titukhina, V. Mishenko, N. Gushina, and S. H. Kaufmann. 2005. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J. Infect. Dis. 192:89-97.
41. Vandiviere, H. M., W. E. Loring, I. Melvin, and S. Willis. 1956. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232:30-37.
42. Voskuil, M. I., K. C. Visconti, and G. K. Schoolnik. 2004. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinburgh) 84:218-227.
43. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
44. Wayne, L. G., and C. D. Sohaskey. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163.
45. Wayne, L. G., and H. A. Sramek. 1994. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:2054-2058.
46. Wiegeshaus, E. H., D. N. McMurray, A. A. Grover, G. E. Harding, and D. W. Smith. 1970. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am. Rev. Respir. Dis. 102:422-429.
47. Zhong, Z., G. E. Arteel, H. D. Connor, M. Yin, M. V. Frankenberg, R. F. Stachlewitz, J. A. Raleigh, R. P. Mason, and R. G. Thurman. 1998. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Am. J. Physiol. 275:F595-F604.